 |
 |
2005
Translational research in oncology comes timely.
Chow LWC and Toi M.
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S263 
Details
Chemoprevention of colorectal cancer; the role of COX 2 inhibitors, from the bench to the bed-side
Arber N
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S332 Details
Correlation between Cox-2 related gene expressions and response to preoperative chemotherapy with celecoxib in primary breast cancer
Bando H , Chow LWC, Higashimoto M, Loo WT, Nakanishi C, Takebayashi Y and Toi M
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S317 Details
Prognostic significance of peritumoral vascular invasion in patients with invasive breast cancer
Bong JG , Choi JW, Ha YG, Lee YS, Park JH, Jeong MH, Lee HO and Oh HG
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S396 Details
Tumor angiogenesis and therapy
Cao Y
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S340-3 Details
Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression
Chan CML , Ma BBY, Wong SC and Chan ATC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S268-71 Details
Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergywith docosahexaenoic acid on the growth of human skin melanoma A-375 cells
Chiu LCM , Tong KF and Ooi VEC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S293-7 Details
Clinicopathologic characteristics of early (40-year-old or younger) onset infiltrating ductal carcinoma of the breast
Choi ES and Kim KC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S394 Details
Aberrant methylation of cyclooxygenase-2 in breast cancer patients
Chow LWC , Zhu L, Loo WTY and Lui ELH
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S264-7 Details
Current directions for COX-2 inhibition in breast cancer
Chow LWC , Loo WTY, Toi M
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S281-4 Details
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients
Chow LWC , Loo WTY , Wai CCY , Lui ELH , Zhu L and Toi M
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S298-301 Details
Serum lipid profiles in patients receiving endocrine treatment for breast cancer?the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial
Chow LWC , Cheng CWL ,Wong JLN and Toi M
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S302-5 Details
Natural killer cells in breast cancer cell growth and metastasis in SCID mice
Dewan MZ , Terunuma H, Ahmed S, Ohba K, Takada M, Tanaka Y, Toi M and Yamamoto N
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S375-9 Details
Gene targeting approach to selectively kill colon cancer cells, with hyperactive K-Ras pathway
Dvory-Sobol H , Kazanov D and Arber N
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S370-4 Details
Metronomic therapy in recurrent and metastatic chemoresistant SCCHN: data from a pilot study
Gluck S , Lau H, Mackinnon J, Syme R and Gluck D
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S319 Details
Changing the gold standard in adjuvant therapy for breast cancer: from tamoxifen to aromatase inhibition
Gluck S
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S321-2 Details
Down syndrome critical region proteinl (DSCR1), a novel VEGF target gene that regulates expression of COX-2 on activated endothelial cells
Hesser BA , Liang XH, Camenisch G, Yang S, Lewin D, Scheller R, Ferrara N and Gerber HP
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S318 Details
Clinical experience for sentinel lymphadenectomy without further axillary dissection in stage I breast cancer
Jeong J , Lee IK, Jung WH, Ryu YH, Oh KK and Lee HD
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S393-4 Details
Expression of cyclin D1, vimentin and thyroglobulin in papillary thyroid cancer and its correlation with clinicobiological factors
Jong Na E and Kim KC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S395 Details
First-line bevacizumab (Avastin) with 5-fluorouracil/leucovorin prolongs progression-free survival in metastatic colorectal cancer (mCRC) patients who are not optimal candidates for irinotecan therapy. ASCO 2004: Abstract No. (3516)
Kabbinavar F , Schulz J, McCleod M, Patel T, Hamm J, Hecht J, Perrou B, Griffing S, Nelson B and Novotny W
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S348 Details
Inhibition effect of human angiogenesis of the cyclooxygenase (COX)-2 inhibitor with MMT cells
Kim SY and Kim TY
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S318 Details
RT-PCR amplification of CK 20 mRNA in the peripheral blood of breast cancer patients: correlation with established prognostic parameters
Kim J , Bae JW, Lee JB, Son GS and Koo BH
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S380-3 Details
Prognostic factors in breast cancer patients following neoadjuvant chemotherapy
Kim JR and Chang ES
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S395-6 Details
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer
Kuroi K , Toi M, Tsuda H, Kurosumi M and Akiyama F
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S387-92 Details
Function of Survivin during embryonic angiogenesis and hematopoiesis in a zebrafish model
Kwan TTF , Cheung CL, Liang R and Leung AYH
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S348-9 Details
Analysis of diagnostic and therapeutic efficacy of mammotome biopsy in breast tumor
Lee YA and Kim KC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S393 Details
Diffusion-weighted magnetic resonance imaging of nasopharyngeal carcinoma
Lee FKH , King AD, Yeung DKW, Ma B and Ahuja AT
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S395 Details
Curcumin synergistically potentiates the growth inhibitory and pro-apoptoticeffects of celecoxib in pancreatic adenocarcinoma cells
Lev-Ari S , Zinger H, Kazanov D, Yona D, Ben-Yosef
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S276-80 Details
CD24 and human carcinoma: tumor biological aspects
Lim SC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S351-4 Details
Expression of c-erbB receptors, MMPs and VEGF in head and neck squamous cell carcinoma
Lim SC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S366-9 Details
The significance of Cox-2 in sentinel lymph node of breast cancer
Liu TA , Yeh DC and Wu CC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S320 Details
The efficacy of Paclitaxel on solid tumour analysed by ATP bioluminescenceassay and VEGF expression: a translational research study
Loo WTY , Fong JHM, Cheung MNB, Chow LWC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S337-9 Details
The value of bone marrow aspirates culture for the detection of bone marrow micrometastasis in breast cancer
Loo WTY , Fong JHM, Zhu L, Cheung MNB and Chow LWC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S384-6 Details
DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma
Lui ELH , Loo WTY, Zhu L, Cheung MNB and Chow LWC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S363-5 Details
NSABP adjuvant trial on the use of COX-2 inhibition in breast cancer
Mamounas EP
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S319-20 Details
Recent findings and future directions in breast cancer chemoprevention
Mamounas EP
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S332-3 Details
Update results of FEC followed by docetaxel neoadjuvant trials for primarybreast cancer
Ohno S , Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, et al.
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S323-4 Details
Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice
Olsen SR
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S306-10 Details
Neoadjuvant trials for discovery and validation of predictive markets?a new NSABP clinical trial paradigm
Paik S
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S325 Details
Development and validation of multi-gene prognostic assay for ER+ breast cancer
Paik S
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S394 Details
Dially disulfide from garlic induces apoptosis through caspase-dependent pathway in human breast cancer cell line, MCF-7
Park HL and Yang JH
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S394 Details
Roles of human vascular formation in tumor growth after cotransplantation of human microvascular endothelial and cancer cells to immunodeficiency mice
Ran Y , Zhong X, Zhang Y, Lou J, Yu L and Yang Z
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S349-50 Details
Pathological evaluation of angiogenesis in human tumor
Sasano H and Suzuki T
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S334-6 Details
COX-2 inhibitors act as radiosensitizer in tumor treatment
Sminia P , Kuipers G, Geldof A, Lafleur V and Slo
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S272-5 Details
COX and friends
Takebayashi Y
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S317-8 Details
The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma
Tang TCM , Poon RTP and Fan ST
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S311-6 Details
Vascular endothelial growth factor and its relationships with endogenousinhibitors in a breast cancer microenvironment manipulated by hormonaltherapy: a hypothetical consideration
Toi M , Bando H, Weich HA
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S344-7 Details
The role of stem cells and gap junctions as targets for cancer chemoprevention and chemotherapy
Trosko JE
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S326-31 Details
Detection of epithelial cell death in the body by cytokeratin 18 measurement
Ueno T , Toi M and Linder S
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S359-62 Details
Identification of IL-8 as a key factor in breast cancer invasion and angiogenesis
Wang SM and Lin Y
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S349 Details
Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts
Wu YL , Fu SL, Zhang YP, Qiao MM and Chen Y
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S289-92 Details
Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients
Zhang J , Ji J, Yuan F, Zhu L, Yan C, Yu YY, Liu
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S285-8 Details
Cyclooxygenase-2: possible predictor related to micrometastasis in breast cancer patients
Zhu L , Loo WTY and Chow LWC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S318 Details
Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes
Zhu L , Loo WTY and Chow LWC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S355-8 Details
